Research round-up

Abstract

In a double-blind, randomised withdrawal study in patients with treatment-resistant depression, Daly and colleagues compared an oral antidepressant plus esketamine nasal spray with oral antidepressant plus placebo nasal spray for the prevention of relapse. Treatment (esketamine nasal spray 56 mg or 84 mg flexible dosing) was initiated in 455 patients. 176 achieved stable remission after 16 weeks and entered the randomised maintenance phase of the study (oral antidepressant plus continued treatment with nasal esketamine or withdrawal of nasal esketamine). 121 participants with stable response also entered the randomised study and were analysed for secondary endpoints. In the primary analysis of participants with stable remission, relapse occurred in 24 (27%) of 90 in the esketamine group and 39 (45%) of 86 in the placebo group experienced relapse (hazard ratio 0·49 [95% CI 0·29–0·84]; p=0·003; NNT=6). Prevalence of maternal mental illness among children and adolescents in the UK between 2005 and 2017: a national retrospective cohort analysisOne in four children aged 0–16 years are exposed to maternal mental illness and the prevalence of diagnosed and treated maternal mental illness is increasing. Policy makers and commissioners should consider this information and channel resources to target individuals in greatest need. Full-Text PDF Open AccessNew WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysisThe burden of mental disorders is high in conflict-affected populations. Given the large numbers of people in need and the humanitarian imperative to reduce suffering, there is an urgent need to implement scalable mental health interventions to address this burden. Full-Text PDF Open Access